Genocea Biosciences
Mar 1, 2017

Genocea to Present at the Cowen and Company 37th Annual Health Care Conference

CAMBRIDGE, Mass., March 01, 2017 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced that Jonathan Poole, chief financial officer, will present a company overview at the upcoming Cowen and Company 37th Annual Health Care Conference on Wednesday, March 8, 2017 at 10:00 a.m. ET in Boston, MA.

A webcast replay will be available on the Genocea website beginning approximately two hours after the event, and will be archived for 30 days.

About Genocea Biosciences Inc.
Genocea is harnessing the power of T cell immunity to develop life-changing vaccines and immunotherapies. T cells are increasingly recognized as a critical element of protective immune responses to a wide range of diseases, but traditional discovery methods have proven unable to identify the targets of such protective immunity. Using ATLASTM, its proprietary technology platform, Genocea identifies these targets to potentially enable the rapid development of medicines to address critical patient needs. Genocea's pipeline includes GEN-003, a novel T cell-enabled immunotherapy for genital herpes currently in Phase 2 clinical development, and earlier-stage investments in immuno-oncology. For more information, please visit the company's website at www.genocea.com.

For media:

Jennifer LaVin

O: 617-715-6687

jennifer.lavin@genocea.com



For investors:

Jonathan Poole

O: 617-876-8191

jonathan.poole@genocea.com

Primary Logo

Source: Genocea Biosciences

News Provided by Acquire Media